On the first day of India's COVID-19 vaccination, 51 people in the capital experienced adverse reactions

　　[Global Times reporter Bofeng Hu] According to a report from The Times of India on the 17th, India officially launched the “world's largest COVID-19 vaccination work” nationwide on the 16th.

According to the plan, 300,000 front-line workers will complete the vaccination on the first day. The goal is to vaccinate about 300 million people by the end of July, including medical staff, people over 50 and other high-risk personnel.

On September 21, 2020 local time, the Indian Taj Mahal reopened to the outside world, symbolizing that everything is back to normal.

The picture shows the staff disinfecting the railings.

　　However, New Delhi TV reported on the 17th that only about 191,000 people completed the vaccination on the first day of vaccination, which is far from the government's established goal.

Reuters reported on the 17th that India’s self-developed CoWIN vaccine management mobile phone application malfunctioned that day, and many people did not receive the vaccination notification.

In addition to the lack of vaccine in the first day, the safety of the vaccine has also been questioned.

According to a report on the website of “India Today” on the 16th, a total of 4,319 medical staff and front-line staff were vaccinated with the new crown vaccine in the Indian capital of New Delhi that day. A total of 51 adverse events were reported after the vaccination. The most adverse events were 11 cases.

　　At present, the two vaccines officially approved by the General Administration of Medicines of India are the Covishield vaccine jointly developed by the University of Oxford and AstraZeneca, and the Covaxin vaccine developed by the Bharat Biotechnology Company of India.

The US "Washington Post" reported that only the Covishield vaccine has passed the Phase III clinical safety and efficacy test, while the Covaxin vaccine has only "completed the early stage test", and no efficacy data has been released so far.

The report also said that the vaccinators of the Covaxin vaccine are required to sign an informed document confirming that "understanding the clinical efficacy of the vaccine has yet to be confirmed."

Somani, director of the General Administration of Drug Administration of India, once stated that "both vaccines can be used safely" and "Covaxin will be vaccinated in a'clinical trial mode'".

But the report quoted an Indian vaccine expert and questioned: "What is the clinical trial model?"